Oral contraceptives and insulin sensitivity.
Cagnacci
Angelo
A
D000293:Adolescent; D000726:Androgen Antagonists / Q000009:adverse effects / Q000627:therapeutic use; D001786:Blood Glucose / Q000032:analysis; D050260:Carbohydrate Metabolism / Q000187:drug effects*; D002986:Clinical Trials as Topic; D003277:Contraceptives, Oral, Combined / Q000009:adverse effects* / Q000627:therapeutic use; D003280:Contraceptives, Oral, Synthetic / Q000009:adverse effects / Q000627:therapeutic use; D017373:Cyproterone Acetate / Q000009:adverse effects / Q000627:therapeutic use; D017135:Desogestrel / Q000009:adverse effects / Q000627:therapeutic use; D005215:Fasting / Q000097:blood; D005260:Female; D005951:Glucose Tolerance Test; D006801:Humans; D006946:Hyperinsulinism / Q000139:chemically induced; D007328:Insulin / Q000097:blood* / Q000378:metabolism; D007333:Insulin Resistance; D000078790:Insulin Secretion; D011085:Polycystic Ovary Syndrome / Q000188:drug therapy* / Q000378:metabolism*
D000726:Androgen Antagonists; D001786:Blood Glucose; D003277:Contraceptives, Oral, Combined; D003280:Contraceptives, Oral, Synthetic; D007328:Insulin; D017373:Cyproterone Acetate; D017135:Desogestrel